Mimvey

SIDE EFFECTS

See BOXED WARNINGS, WARNINGS and PRECAUTIONS.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Adverse events reported with estradiol and norethindrone acetate 1 mg/0.5 mg by investigators in the Phase 3 studies regardless of causality assessment are shown in Table 6.

TABLE 6 : ALL TREATMENT-EMERGENT ADVERSE EVENTS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF ≥ 5% WITH ESTRADIOL AND NORETHINDRONE ACETATE 1 MG/0.5 MG

  Endometrial
Hyperplasia Study
(12-Months)
Vasomotor
Symptoms Study
(3-Months)
Osteoporosis Study (2-Years)
Estradiol and Norethindrone Acetate 1 mg/0 .5 mg
(n=295)
1 mg E2
(n=296)
Estradiol and Norethindrone Acetate 1 mg /0.5 mg
(n=29)
Placebo
(n=34)
Estradiol and Norethindrone Acetate 1 mg/0 .5 mg
(n=47)
Placebo
(n=48)
Body as a Whole
Back Pain 6% 5% 3% 3% 6% 4%
Headache 16% 16% 17% 18% 11% 6%
Digestive System
Nausea 3% 5% 10% 0% 11% 0%
Gastroenteritis 2% 2% 0% 0% 6% 4%
Nervous System
Insomnia 6% 4% 3% 3% 0% 8%
Emotional Lability 1% 1% 0% 0% 6% 0%
Respiratory System
Upper Respiratory Tract Infection 18% 15% 10% 6% 15% 19%
Sinusitis 7% 11% 7% 0% 15% 10%
Metabolic and Nutritional
Weight Increase 0% 0% 0% 0% 9% 6%
Urogenital System
Breast Pain 24% 10% 21% 0% 17% 8%
Post- Menopausal Bleeding 5% 15% 10% 3% 11% 0%
Uterine 5% 4% 0% 0% 4% 8%
Fibroid
Ovarian Cyst 3% 2% 7% 0% 0% 8%
Resistance Mechanism
Infection Viral 4% 6% 0% 3% 6% 6%
Moniliasis Genital 4% 7% 0% 0% 6% 0%
Secondary Terms
Injury Accidental 4% 3% 3% 0% 17%* 4%*
Other Events 2% 3% 3% 0% 6% 4%
*including one upper extremity fracture in each group

Adverse events reported with estradiol and norethindrone acetate 0.5 mg/0.1 mg by investigators during the Phase 3 study regardless of causality assessment are shown in Table 7.

TABLE 7 : ALL TREATMENT-ADVERSE EVENTS REGARDLESS OF RELATIONSHIP REPORTED AT A FREQUENCY OF ≥ 5% WITH ESTRADIOL AND NORETHINDRONE ACETATE 0.5 MG/0.1 MGG

  Estradiol and Norethindrone Acetate 0 .5 mg /0.1 mg
(n=194)
Placebo
(n=200)
Body as a Whole
Back Pain 10% 4%
Headache 22% 19%
Pain in extremity 5% 4%
Digestive System
Nausea 5% 4%
Diarrhea 6% 6%
Respiratory System
Nasopharyngitis 21% 18%
Urogenital System
Endometrial thickening 10% 4%
Vaginal hemorrhage 26% 12%

The following adverse reactions have been reported with estrogen and/or progestin therapy:

Genitourinary System

Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; premenstrual-like syndrome; cystitis-like syndrome; ovarian cancer; endometrial hyperplasia; endometrial cancer.

Breasts

Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer.

Cardiovascular

Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction, stroke; increase in blood pressure.

Gastrointestinal

Nausea, vomiting; changes in appetite; cholestatic jaundice; abdominal pain/cramps, flatulence, bloating; increased incidence of gallbladder disease; pancreatitis; enlargement of hepatic hemangiomas.

Skin

Chloasma or melasma that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; seborrhea; hirsutism; itching; skin rash; pruritus.

Eyes

Retinal vascular thrombosis, intolerance to contact lenses.

Central Nervous System

Headache; migraine; dizziness; mental depression; chorea; insomnia; nervousness; mood disturbances; irritability; exacerbation of epilepsy; probable dementia.

Miscellaneous

Increase or decrease in weight; aggravation of porphyria; edema; leg cramps; changes in libido; fatigue; reduced carbohydrate tolerance; anaphylactoid/anaphylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides; back pain; arthralgia; myalgia.

Read the Mimvey (estradiol and norethindrone acetate tablets) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Drug/Laboratory Test Interactions

  1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
  2. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T levels (by column or by radioimmunoassay), or T levels by radioimmunoassay. T resin uptake is decreased, reflecting the elevated TBG. Free T and free T concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
  3. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), SHBG) leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/rennin substrate, alpha-1 antitrypsin, ceruloplasmin).
  4. Increased plasma HDL and HDL cholesterol sub-fraction concentration, reduced LDL cholesterol concentration, increased triglyceride levels.
  5. Impaired glucose tolerance.
  6. Reduced response to metyrapone test.

Last reviewed on RxList: 4/1/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations